# US 2014/0193367 A1 · Method for reducing uremic toxins by probiotic composition and the manufacturing method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193367 A1
- Document ID: US20140193367A1
- Status: Published application
- Kind: A1
- Application number: 13/835,316
- Filed: 2013-03-15
- Published: 2014-07-10
- Earliest claimed: 2013-01-10
- Assignees: National Taiwan University; Conmed Pharmaceutical & Bio-Medical Corporation
- Applicants: National Taiwan University
- Inventors: Chen-Yu Fang; Bao-Ji Chen; Ming-Ju Chen; Je-Ruei Liu
- Web page: https://patentgrep.com/patent/US20140193367A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 39/02: Antidotes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a probiotic composition for reducing uremic toxins and the manufacturing method thereof. The probiotic composition comprises at least one selected from the group consisting of: Lactobacillus plantarum BCRC 12251, Lactobacillus paracasei BCRC 12188, Streptococcus thermophilus BCRC 13869 and pharmaceutically acceptable vehicles, excipients, diluents, adjuvants, etc. The invention further relates to a probiotic composition consisted of Lactobacillus plantarum BCRC 12251, Lactobacillus paracasei BCRC 12188, Streptococcus thermophilus BCRC 13869 and pharmaceutically acceptable vehicles, excipients, diluents, adjuvants, etc. In addition, the invention relates to a novel use of the probiotic composition for reducing uremic toxins, wherein the uremic toxins are protein-bound uremic toxins.

## Claims

### Claim 1

A method for reducing uremic toxins by using probiotic compositions, wherein the probiotic composition comprises at least one selected from the group consisting of: Lactobacillus plantarum BCRC 12251, Lactobacillus paracasei BCRC 12188, Streptococcus thermophilus BCRC 13869 and pharmaceutically acceptable vehicles, excipients, diluents, and adjuvants.

### Claim 2 (depends on 1)

The method of claim 1 wherein the uremic toxins are protein-bound uremic toxins.

### Claim 3 (depends on 2)

The method of claim 2 wherein the protein-bound uremic toxins are indoxyl sulfate, p-cresol and phenol.

### Claim 4

A probiotic composition for reducing uremic toxins, and said composition comprises Lactobacillus plantarum BCRC 12251, Lactobacillus paracasei BCRC 12188, Streptococcus thermophilus BCRC 13869 and pharmaceutically acceptable vehicles, excipients, diluents and adjuvants.

### Claim 5 (depends on 4)

The probiotic composition of claim 4 wherein the uremic toxins are protein-bound uremic toxins.

### Claim 6 (depends on 5)

The probiotic composition of claim 5 wherein the protein-bound uremic toxins are indoxyl sulfate, p-cresol and phenol.

### Claim 7 (depends on 4)

The probiotic composition of claim 4 wherein the concentrations of the probiotics are 107-1010 CFU/mL.

### Claim 8 (depends on 4)

The probiotic composition of claim 4 wherein the amounts of Lactobacillus plantarum BCRC 12251, Lactobacillus paracasei BCRC 12188, and Streptococcus thermophilus BCBR 13869 are 40-60%, 20-30% and 20-30%, respectively.